The trial showed statistical significance that the product provided pain relief after surgery in the treatment group using ELI-200 compared to the placebo group. The company said secondary
As on June 30, 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally. This includes
Imperial has secured £3m in funding from the Wellcome Trust Seeding Drug Discovery program to build upon the research of professor Michael Schneider, the British Heart Foundation Simon
The National Cancer Institute (NCI) is currently carrying out two Phase 1-2a clinical trials of TCR-based product candidates targeting the MAGE antigens under a cooperative research and development
The study was intended to see if a combination of ganetespib and docetaxel would work better than docetaxel alone for advanced non-small cell lung adenocarcinoma. Synta halted the
China-based Yabao will co-develop Lilly’s sodium-glucose linked transporter inhibitor (SGLT1) molecule. Under the deal, Yabao secures the rights to develop and commercialize the SGLT1 compound in China, while
SV Life Sciences will manage the Dementia Discovery Fund (DDF), whose investors include the government’s Department of Health (DoH), Alzheimer’s Research UK, Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly,
The facility, which is expected to start operations in 2017, will manufacture about 40 million packs and 850 million tablets of around 30 medicines every year. It represents
The company expects to complete the study in the second half of 2016. It is a multi-center, single-arm, open-label trial in healthy women at least 18 years old
The collaboration will use Luc’s capability platform in NMDA-receptor modulation. The company will focus its in-house research efforts on programs to develop first-in-class therapeutics for addressing cognitive impairment
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.